87 reports of this reaction
2.6% of all ALFUZOSIN HYDROCHLORIDE reports
#5 most reported adverse reaction
FATIGUE is the #5 most commonly reported adverse reaction for ALFUZOSIN HYDROCHLORIDE, manufactured by Cipla USA Inc.. There are 87 FDA adverse event reports linking ALFUZOSIN HYDROCHLORIDE to FATIGUE. This represents approximately 2.6% of all 3,364 adverse event reports for this drug.
Patients taking ALFUZOSIN HYDROCHLORIDE who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is a less commonly reported adverse event for ALFUZOSIN HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to fatigue, the following adverse reactions have been reported for ALFUZOSIN HYDROCHLORIDE:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 87 FDA reports for ALFUZOSIN HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 2.6% of all adverse event reports for ALFUZOSIN HYDROCHLORIDE, making it a notable side effect.
If you experience fatigue while taking ALFUZOSIN HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.